155.42
Schlusskurs vom Vortag:
$165.98
Offen:
$164.72
24-Stunden-Volumen:
1.09M
Relative Volume:
0.76
Marktkapitalisierung:
$12.55B
Einnahmen:
$8.19B
Nettoeinkommen (Verlust:
$758.19M
KGV:
16.93
EPS:
9.18
Netto-Cashflow:
$1.06B
1W Leistung:
-14.37%
1M Leistung:
+3.54%
6M Leistung:
-20.68%
1J Leistung:
-50.27%
Icon Plc Stock (ICLR) Company Profile
Firmenname
Icon Plc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ICLR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ICLR
Icon Plc
|
155.42 | 12.91B | 8.19B | 758.19M | 1.06B | 9.18 |
![]()
TMO
Thermo Fisher Scientific Inc
|
448.94 | 176.13B | 43.21B | 6.58B | 6.17B | 17.29 |
![]()
DHR
Danaher Corp
|
195.17 | 142.52B | 24.01B | 3.41B | 4.86B | 4.70 |
![]()
IDXX
Idexx Laboratories Inc
|
624.19 | 51.36B | 4.04B | 985.66M | 774.34M | 12.01 |
![]()
A
Agilent Technologies Inc
|
113.23 | 32.64B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
177.49 | 31.27B | 15.50B | 1.33B | 2.16B | 7.34 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2025-04-29 | Herabstufung | JP Morgan | Overweight → Neutral |
2025-04-14 | Herabstufung | TD Cowen | Buy → Hold |
2025-04-10 | Herabstufung | Barclays | Overweight → Equal Weight |
2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
2025-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
2024-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2024-10-14 | Eingeleitet | Redburn Atlantic | Neutral |
2024-09-18 | Eingeleitet | Leerink Partners | Outperform |
2024-06-06 | Eingeleitet | Goldman | Buy |
2023-12-15 | Eingeleitet | Truist | Buy |
2023-09-13 | Eingeleitet | TD Cowen | Outperform |
2023-01-17 | Hochstufung | Barclays | Equal Weight → Overweight |
2023-01-13 | Hochstufung | Barclays | Equal Weight → Overweight |
2022-11-09 | Hochstufung | BofA Securities | Neutral → Buy |
2022-09-07 | Eingeleitet | UBS | Buy |
2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
2022-05-24 | Eingeleitet | Guggenheim | Buy |
2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2022-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
2021-09-27 | Hochstufung | JP Morgan | Neutral → Overweight |
2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
2021-07-23 | Hochstufung | Citigroup | Neutral → Buy |
2021-07-14 | Eingeleitet | Citigroup | Neutral |
2021-04-13 | Fortgesetzt | BofA Securities | Neutral |
2021-04-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2021-03-08 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2021-03-03 | Eingeleitet | Barclays | Equal Weight |
2021-03-01 | Hochstufung | UBS | Neutral → Buy |
2021-02-26 | Hochstufung | Truist | Hold → Buy |
2020-07-24 | Herabstufung | BofA Securities | Buy → Neutral |
2020-04-20 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2020-03-26 | Hochstufung | Barclays | Equal Weight → Overweight |
2020-03-02 | Eingeleitet | Deutsche Bank | Hold |
2020-01-27 | Herabstufung | SunTrust | Buy → Hold |
2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
2020-01-07 | Eingeleitet | Citigroup | Neutral |
2019-09-23 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
2019-07-26 | Hochstufung | UBS | Sell → Neutral |
2019-01-25 | Hochstufung | Mizuho | Neutral → Buy |
2018-10-26 | Hochstufung | Evercore ISI | In-line → Outperform |
2018-10-09 | Eingeleitet | UBS | Sell |
2018-04-03 | Herabstufung | Evercore ISI | Outperform → In-line |
2018-02-15 | Bestätigt | Mizuho | Neutral |
2018-01-19 | Eingeleitet | Evercore ISI | Outperform |
2017-10-27 | Bestätigt | Barclays | Equal Weight |
2017-09-11 | Eingeleitet | BofA/Merrill | Buy |
2017-07-31 | Hochstufung | SunTrust | Hold → Buy |
2017-07-27 | Bestätigt | Mizuho | Neutral |
2017-06-29 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Icon Plc Aktie (ICLR) Neueste Nachrichten
Fund Update: First Pacific Advisors, LP added 417,173 shares of ICON PLC ($ICLR) to their portfolio - Quiver Quantitative
ICON Plc’s Earnings Call: Balancing Achievements and Challenges - TipRanks
ICON plc: Initiation of Coverage- Capitalizing On Opportunities in China, A Critical Growth Market! - smartkarma.com
ICON Plc's Q2 Earnings Call: Balancing Growth and Challenges - AInvest
Deutsche Bank Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $210 - 富途牛牛
Leerink Partners Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $240 - 富途牛牛
ICON plc’s SWOT analysis: navigating challenges in CRO stock landscape By Investing.com - Investing.com India
ICON plc’s SWOT analysis: navigating challenges in CRO stock landscape - Investing.com
ICON's Intrinsic Value Estimated at $278, 33% Undervalued by Current Share Price - AInvest
Icon price target raised to $225 from $173 at Mizuho - TipRanks
ICON plc Q2 2025 Financial Results: Revenue Up 0.8%, Net Income Rises 30.7% - AInvest
UBS Raises Icon PLC Price Target to $240, Maintains 'Buy' Rating - AInvest
Icon PLC (ICLR) Q2 Report: Barclays Raises Price Target to $180, Maintains Equal Weight Rating - AInvest
ICON plc Reports Strong Q2 2025 Financial Results - The Globe and Mail
ICON plc Expands Share Repurchase Program and Resumes COVID Vaccine Study - The Globe and Mail
ICON plcOrdinary Shares (Nasdaq:ICLR) Stock Quote - FinancialContent
Evercore Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $240 - 富途牛牛
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $209 to $240 - 富途牛牛
Icon PLC (ICLR) Q2 2025 Earnings Call Highlights: Navigating Cha - GuruFocus
Icon plc's Shares Surge 17.2% Amid Investor Optimism - AInvest
Icon Plc Announces Kedrion IVIg 10% Study for Chronic ITP: Market Implications - AInvest
ICON Expects $8B in Revenue for Full Year, Driven by Biotech Wins and Pharma Partnerships - AInvest
ICON plc Announces Successful AGM Resolutions - The Globe and Mail
ICON Stock Surge: Future Safe or Risky? - StocksToTrade
ICON’s Unexpected Surge: What’s Behind the Jump? - timothysykes.com
ICON Stock Up After Q2 Results Signal Growing Confidence In Biopharma Recovery - Benzinga
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $170 to $224 - 富途牛牛
Icon plc (ICLR) Shares Surge Over 17% Amid Investor Optimism | ICLR Stock News - GuruFocus
Icon Plc’s New Study on Kedrion IVIg 10% for Chronic ITP: What Investors Need to Know - TipRanks
ICON’s Earnings Beat and Strategic Moves: A Market Outlook - StocksToTrade
RPM International Posts Better-Than-Expected Earnings, Joins ICON, MaxLinear, Nasdaq And Other Big Stocks Moving Higher On ThursdayArrive AI (NASDAQ:ARAI), ASGN (NYSE:ASGN) - Benzinga
Growth or Bubble? Decoding the Rapid Rise of ICLR Stock - StocksToTrade
Icon PLC Q2 Earnings Exceed Projections with $183 Million ProfitNews and Statistics - IndexBox
S&P 500 Futures Climb in Premarket Trading; West Pharmaceutical Svcs, Icon PLC Lead - Barron's
ICON: Lower Guidance Downside & Expanded Repurchase Plan (ICLR) - Seeking Alpha
Icon PLC: Q2 Earnings Snapshot - CTPost
Icon Earnings: Shares Rise 14% on Strong Business Wins Despite Elevated Cancellations - Morningstar
ICON Announces Results of Annual General Meeting - BioSpace
William Blair Maintains Icon PLC(ICLR.US) With Buy Rating - 富途牛牛
ICON PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Icon PLC (ICLR) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
ICON plc Reports Strong Q2 2025 Financial Results and Updates Guidance - TipRanks
ICON PLC earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria
SUI Insider Grant: President Gets 4,788 Restricted Shares at $125.06 | ICLR SEC FilingForm 6-K - Stock Titan
ICON Reports Second Quarter 2025 Results | ICLR Stock News - GuruFocus
ICON's Resilience in a Turbulent Market: A Case for Strategic Investment - AInvest
ICON Announces Results of Annual General Meeting | ICLR Stock News - GuruFocus
ICON Clinical Research Earnings Soar 31% as Business Wins Hit $3B, Expands $1B Buyback Program - Stock Titan
ICON plc Stock Takes Center Stage. What’s Next? - StocksToTrade
ICON plc’s Market Surge: Examining Strong Moves - timothysykes.com
ICON plc Emerges as Phase 1 Clinical Trials Leader in New Benchmark Report - StocksToTrade
Finanzdaten der Icon Plc-Aktie (ICLR)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):